SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended  October 31, 2017

 

or

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File Number  000-53376

 

ETERNITY HEALTHCARE INC.

(Exact name of registrant as specified in its charter)

 

Nevada   75-3268426
(State or other jurisdiction of
incorporation or organization)
  (IRS Employer
Identification No.)

 

c/o Team Youn Bio Medicine International Corp. Limited
Flat/Rm 1006 10/F, Hang Seng Tsim Sha Tsui Bldg

18 Carnarvon Road

Tsim Sha TsuiI, KL, Hong Kong

  N/A
(Address of principal executive offices)   (Zip Code)

 

+8613691884662

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ YES  ☐ NO

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ YES  ☐ NO

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller Reporting Company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B)  ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ YES  ☒ NO

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS

 

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. ☒ YES  ☐ NO

 

APPLICABLE ONLY TO CORPORATE ISSUERS

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

As of December 29, 2017, we had outstanding 70,929,868 shares of common stock. 

 

 

 

 

 

TABLE OF CONTENTS

 

PART I – FINANCIAL INFORMATION 1
Item 1. Financial Statements 1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 11
Item 3. Quantitative and Qualitative Disclosures About Market Risk 15
Item 4. Controls and Procedures 15
   
PART II – OTHER INFORMATION 16
Item 1. Legal Proceedings 16
Item 1A. Risk Factors 16
Item 2. Unregistered Sales of Equity Securities 16
Item 3. Defaults Upon Senior Securities 16
Item 4. Mining Safety Disclosures 16
Item 5. Other Information 16
Item 6. Exhibits 16

 

 

 

 

Forward-Looking Statements

 

This quarterly report on Form 10-Q and other reports filed by our company from time to time with the United States Securities and Exchange Commission (the “SEC”) contain or may contain forward-looking statements (collectively the “Filings”) and information that are based upon beliefs of, and information currently available to, our company’s management as well as estimates and assumptions made our company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used in the filings, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions as they relate to our company or our company’s management identify forward-looking statements. Such statements reflect the current view of our company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks contained in the “Risk Factors” section of our company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2017, relating to our company’s industry, our company’s operations and plan of operations, and any businesses that our company may acquire. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

 

Although we believe that the expectations reflected in the forward-looking statements are reasonable, our company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, our company does not intend to update any of the forward-looking statements to conform these statements to actual results.

 

Our interim consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the interim consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our interim consolidated financial statements would be affected to the extent there are material differences between these estimates and actual results. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does not require management’s judgment in its application. There are also areas in which management’s judgment in selecting any available alternative would not produce a materially different result. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report.

 

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars unless otherwise stated. All references to “common stock” refer to the common shares in our capital stock.

 

As used in this quarterly report, the terms, “we”, “us”, “our” and “our company” refer to Eternity Healthcare Inc., unless the context clearly requires or states otherwise.

 

 

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

 

Eternity Healthcare Inc.

Consolidated Balance Sheet

(Expressed in U.S. Dollars)

 

 

    October 31,     April 30,  
    2017     2017  
    $     $  
    (Unaudited)        
Assets            
Current assets            
Current assets of discontinued operations (note 10)     -       203,980  
                 
Total assets     -       203,980  
                 
Liabilities                
Current liabilities                
Accounts payable and accrued liabilities (Note 6)     16,579       -  
Due to related parties (Note 7)     842,663       851,787  
Current liabilities of discontinued operations (Note 10)     -       128,607  
      859,242       980,394  
                 
Shareholders’ equity (deficit)                
Capital stock (Note 8)                
                 
Authorized 300,000,000 common shares, par value $ 0.001 Issued and outstanding                
October 31, 2017 – 70,929,868 common shares                
April 30, 2017 – 70,929,868 common shares     70,930       70,930  
Additional paid-in capital     1,946,740       1,946,740  
Accumulated other comprehensive gain     -       52,809  
Accumulated deficit     (2,876,912 )     (2,846,893 )
                 
Total stockholders’ (deficit)     (859,242 )     (776,414 )
                 
Total liabilities and stockholders’ equity (deficit)     -       203,980  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

  1

 

 

 

Eternity Healthcare Inc.

Consolidated Statements of Operations and Comprehensive Income

(Expressed in U.S. Dollars)

(Unaudited)

 

 

    For the three     For the three     For the six     For the six  
    months ended     months ended     months ended     months ended  
    October 31,
2017
    October 31,
2016
    October 31,
2017
    October 31,
2016
 
    $     $     $     $  
Sales                        
Product sales     -       -       -       -  
Cost of goods sold     -       -       -       -  
Gross margin     -       -       -       -  
                                 
Operating Expenses                                
General and administrative     2,448       1,683       9,898       3,588  
Professional fees     18,305       9,396       25,546       27,706  
Total operating expenses     20,753       11,079       35,444       31,294  
                                 
Net loss from continued operations     (20,753 )     (11,079 )     (35,444 )     (31,294 )
                                 
Other income (expenses)                                
Interest expense     (9,000 )     (11,026 )     (17,737 )     (22,124 )
Interest income     -       94       -       620  
Foreign exchange gain     75,284       -       75,284          
Gain on sale of intellectual property     31,836       -       31,836       -  
      98,120       (10,932 )     89,383       (21,504 )
                                 
Net income (loss) for the period from continued Operations     77,367       (22,011 )     53,939       (52,798 )
                                 
Net income (loss) for the period from discontinued Operations (Note 10)     -       (94,163 )     (83,957 )     (166,809 )
                                 
Total income (loss) for the period     77,367       (116,174 )     (30,018 )     (219,607 )
                                 
Other comprehensive income (loss)     35,581       20,842       (52,809 )     46,094  
                                 
Comprehensive income (loss) for the period     112,948       (95,332 )     (82,827 )     (173,513 )
                                 
Net loss per share - basic and diluted                                
Continued Operations     0.001       (0.000 )     0.001       (0.001 )
Discontinued operation     0.000       (0.002 )     (0.001 )     (0.002 )
Total     0.001       (0.002 )     0.000       (0.003 )
Weighted average number of common shares
Outstanding - basic
    70,929,868       66,429,868       70,929,868       66,429,868  
Weighted average number of common shares
Outstanding - diluted
    72,929,868       66,429,868       70,929,868       66,429,868  

 

The accompanying notes are an integral part of these consolidated financial statements

 

  2

 

 

 

Eternity Healthcare Inc.

Consolidated Statements of Cash Flows

( Expressed in U.S. Dollars)

(Unaudited)

 

 

    For the six   For the six
    months ended   months ended
    October 31,   October 31,
    2017   2016
    $   $
Operating activities        
Net income (loss) for the period from continued operations     53,939       (52,798 )
Adjustments to reconcile to net loss to net cash used in operating activities                
Foreign exchange adjustment     51,151       -  
Gain on sale of intellectual property     (31,836 )     -  
Impairment of inventory     55,210       -  
Expenses paid on behalf of the Company by related parties     -       8,695  
Changes in operating assets and liabilities                
GST/HST receivable     1,258          
Inventory     (9,454 )     (26,645 )
Prepaid expenses     24,230       10,270  
Accounts payable and accrued liabilities     (112,029 )     14,465  
Accounts receivable     -       1,376  
                 
Net cash from (used in) operating activities     32,469       (44,637 )
                 
Investing activities                
Short-term investments     -       306,739  
                 
Net cash from investing activities     -       306,739  
                 
Financing activities                
Proceeds from related party payables     -       99,690  
Repayments on related party payables     -       (113,784 )
                 
Net cash used in financing activities     -       (14,094 )
                 
Effect of exchange rate changes on cash     -       (14,549 )
                 
Increase (decrease) in cash from continued operations    

32,469

      233,459  
Increase (decrease in cash from discontinued operations                
Net income (loss) for period from continued operations     (83,957 )     (166,809 )
Adjustment for cash balance of subsidiary     (96,631 )     -  
                 
Net cash from discontinued operations     (180,588 )     (211,446 )
                 
Cash, beginning of period     148,119       259,040  
                 
Cash, end of period     -       325,690  

 

The accompanying notes are an integral part of these consolidated financial statements

 

  3

 

 

 

Eternity Healthcare Inc.

Notes to the Consolidated Financial Statements

October 31, 2017

( Expressed in U.S. Dollars)

(Unaudited)

 

 

1. Nature and continuance of operations

 

Eternity Healthcare Inc. (the “Company”) was incorporated under the laws of the State of Nevada on October 24, 2007 under the name Kid’s Book Writer, Inc. On September 23, 2010, the Company changed its name to Eternity Healthcare Inc., and affected a reverse stock split of the issued and outstanding common stock at a factor of 10 old shares for 1 new share. The Company is focused on offering a range of medical devices and diagnostics.

 

On December 13, 2010, pursuant to the terms of a share exchange agreement, the Company acquired 100% of the issued and outstanding common stock of Eternity Healthcare Inc., a company incorporated under the laws of the Province of British Columbia on December 10, 2009 (“Eternity BC”), for 60,000,000 shares of its own common stock, which were distributed to the shareholders of Eternity BC (the “Share Exchange Agreement”).

 

The Share Exchange Agreement, which represents a majority of the then issued and outstanding shares of the Company, constituted a change in control of the Company. The acquisition of Eternity BC was accounted for as a reverse acquisition in accordance with Accounting Standards Codification (“ASC”) 805-40, “Business Combinations”. The Company determined for accounting and reporting purposes that Eternity BC is the acquirer because of the significant holdings and influence of the control group of the Company before and after the acquisition. As a result of the transaction, Eternity BC shareholders own approximately 94.4% of issued and outstanding common stock of the Company on a diluted basis.

 

On June 25, 2012, the Company entered into a marketing agreement with Mika Medical Company of Korea to be the sole marketer of a new line of needle-free injection product for North America. Furthermore, the marketing agreement was extended to some European countries (German, France, and Spain) in December 2012. Additionally, the Company obtained the rights to market the products throughout the world with an amendment dated December 20, 2012.

 

Since signing the Distribution Agreement with Mika Medicals, the Company has emerged in organizational and start up activities, including developing a new business plan, making arrangements for office space and raising additional capital.

 

On June 5, 2014 the Company registered to operate within the state of Arizona with the intention to take over operations within the United States from the Canadian subsidiary. Beginning January 1, 2016 the Company took over operations within the United States from the BC Company.

 

On August 23, 2017, the Company disposed of its intellectual property and its subsidiary, Eternity Healthcare Inc. (British Columbia). The Company received gross proceeds of $ 31,836 ($ 40,000 CAD) in relation to the intellectual property and $ 47,754 ($ 60,000 CAD) for the shares of the subsidiary. The proceeds were paid by a reduction in the amount owed to a related party.

 

The Company has net loss of $ 30,018 for the six months ended October 31, 2017 (October 31, 2016 - net loss of $ 219,607) and has a working capital deficit of $ 859,242 as at October 31, 2017 (April 30, 2017 - $ 776,414).

 

2. Condensed financial statements

 

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, result of operations, and cash flows at October 31, 2017, and for all periods presented herein, have been made.

 

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s April 30, 2017 audited financial statements. The results of operations for the period ended October 31, 2017 and 2016 are not necessarily indicative of the operating results for the full year.

 

  4

 

 

 

Eternity Healthcare Inc.

Notes to the Consolidated Financial Statements

October 31, 2017

( Expressed in U.S. Dollars)

(Unaudited)

 

 

3. Going concern

 

The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on its obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

 

4. Significant accounting policies

 

The following is a summary of significant accounting policies used in the preparation of these consolidated financial statements.

 

Basis of presentation

 

These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and are expressed in U.S. dollars.

 

Principles of consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Eternity Healthcare Inc. (BC) until the date of sale on August 23, 2017 and Eternity Healthcare Inc. (Arizona). All significant intercompany balances and transactions have been eliminated in consolidation.

 

Cash and cash equivalents

 

Cash and cash equivalents include highly liquid investments with original maturities of three months or less.

 

Inventory

 

Inventory is stated at the lower of cost or market with cost determined under the weighted average cost method.

 

Revenue

 

Revenue is recognized at the point of sale and includes shipping revenue for the delivery to the purchaser. Total revenues do not include sales taxes as we serve as a pass-through conduit for collecting and remitting sales taxes. We recognize retail sales returns as they occur as historical returns have been negligible. In accordance with SAB 104, revenue is recognized when (i) there is persuasive evidence that an arrangement exists, (ii) delivery has occurred or service has been rendered, (iii) the price is fixed or determinable, and (iv) collection is reasonably assured.

 

  5

 

 

 

Eternity Healthcare Inc.

Notes to the Consolidated Financial Statements

October 31, 2017

(Expressed in U.S. Dollars)

(Unaudited)

 

   

4. Significant accounting policies - continued

 

Foreign currency translation

 

The Company’s functional and presentational currency is the U.S. dollar. All transactions initiated in other currencies are translated into the reporting currency in accordance with ASC 830, “Foreign Currency Matters” as follows:

 

i) Assets and liabilities at the rate of exchange in effect at the balance sheet date; and
ii) Revenue and expense items at rate of exchange at the dates on which those elements are recognized.

 

Gains and losses on translation are included in other comprehensive income (loss) in stockholders’ deficiency for the period.

 

Fair value

 

The carrying value of cash and cash equivalents, accounts receivable, accounts payable and due to related parties approximate their fair values because of the short-term maturity of these financial instruments.

 

Interest rate risk

 

The company is not exposed to significant interest rate risk due to the short-term maturity of its monetary assets and liabilities.

 

Credit risk

 

Credit risk is the risk of loss associated with counterparty’s inability to fulfill its payment obligations. The Company’s credit risk is primarily attributable to cash and accounting receivable. Management believes that the credit risk concentration with respect to financial instruments included in cash and accounts receivable is remote.

 

Currency risk

 

The Company’s operating expenses are primarily incurred in Canadian dollars, and fluctuation of the Canadian dollar in relation to the United States dollar will have an impact upon the profitability of the Company and may also have an effect of the value of the Company’s. The Company has not entered into any agreements or purchased any instruments to hedge possible currency risk. At October 31, 2017 1 United States dollar was equal to 1.3403 Canadian dollars.

 

Basic and diluted net income (loss) per share

 

The Company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share”. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As at October 31, 2017 there were outstanding stock options and warrants totaling 2,200,000 common shares (Notes 9 and 10).

 

Research and development

 

The Company recognizes research and development costs in accordance with ASC 730, “Research and Development”, which requires the Company to expense research and development costs as they are incurred.

 

  6

 

 

 

Eternity Healthcare Inc.

Notes to the Consolidated Financial Statements

October 31, 2017

(Expressed in U.S. Dollars)

(Unaudited)

 

 

4. Significant accounting policies - continued

 

Income taxes

 

Deferred income taxes are reported for timing differences between items of income or expense reported in the financial statements and those reported for income tax purposes in accordance with ASC 740, “Income Taxes”, which requires the use of the asset/liability method of accounting for income taxes. Deferred income taxes and tax benefits are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and for tax losses and credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company provides for deferred taxes for the estimated future tax effects attributable to temporary differences and carry-forwards when realization is more likely than not.

 

Comprehensive loss

 

ASC 22, “Comprehensive Income”, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As at October 31, 2017, the Company has items that represent a comprehensive income (loss) and, therefore, has included a schedule of comprehensive income (loss) in the financial statements.

 

Use of estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenditures during the reporting period. Actual results could differ from these estimates.

 

Segments of an enterprise and related information

 

ASC 280, “Segment Reporting” establishes guidance for the way that public companies report information about operating segments in annual financial statements and requires reporting of selected information about operating segments in interim financial statements issued to the public. It also establishes standards for disclosures regarding products and services, geographic areas and major customers. ASC 280 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company has evaluated this Codification and does not believe it is applicable at this time.

 

Recently Enacted Accounting Standards

 

Our company does not expect the adoption of any other recent accounting pronouncements to have a material impact on its financial statements.

 

  7

 

 

 

Eternity Healthcare Inc.

Notes to the Consolidated Financial Statements

October 31, 2017

(Expressed in U.S. Dollars)

(Unaudited)

 

 

5. Inventory

 

Inventory consists of needle free injection products that are held for resale. Inventory is stated at the lower of cost or market with cost determined under the weighted average cost method. As of October 31, 2017 and April 30, 2017 inventory consisted of the following:

 

      October 31,     April 30,  
      2017     2017  
      $     $  
  Raw Material         -       -  
  Work in progress     -       -  
  Finished goods     -       30,283  
  Reserve for obsolescence     -       -  
                   
        -       30,283  

 

During the period ending October 31, 2017, the Company recognized a $ 55,210 write-down of inventory.

 

6. Accounts payable and accrued liabilities

 

Accounts payable and accrued liabilities are non-interest bearing, unsecured, and have settlement dates within one year.

 

7. Due to related parties and related party transactions

 

During the period-ended October 31, 2017, the Company sold its wholly owned subsidiary, Eternity Healthcare Inc. (BC), and certain intellectual property owned by the Company to a related party for $100,000 Canadian Dollars. In addition, the Company received $ Nil in additional cash loans from related parties of the Company and made repayments to related parties of $ Nil. Total related party notes payable as of October 31, 2017 were $ 842,663. $ 698,040 ($ 900,000 CAD) of this balance is interest bearing at 5% per year on the principle balance, unsecured and has no fixed terms of repayment. Effective May 1, 2016, the excess over $ 900,000 CAD is a non-interest bearing balance, unsecured with no fixed terms of repayment. During the period- ended October 31, 2017, the Company recorded interest expense of $ 9,000 with regard to the outstanding related party loans.

 

8. Capital stock

 

Authorized

 

The total authorized capital is 300,000,000 common shares with a par value of $ 0.001 per common share.

 

  8

 

 

 

Eternity Healthcare Inc.  

Notes to the Consolidated Financial Statements

October 31, 2017

(Expressed in U.S. Dollars)

(Unaudited)

 

  

9. Warrants

 

During the year-ended April 30, 2017, the Company granted 2,000,000 warrants for services. The fair value of the stock warrants granted was estimated at $ 119,649 on the date granted using the Black-Scholes pricing model, with the following assumptions used for the valuation: exercise price of $ 0.001 per share, average risk-free interest rate of 0.573%, expected dividend yield of zero, expected lives of three years and an average expected volatility of 247.04%. As at October 31, 2017, $nil remained as a prepaid expense.

 

A summary of the status of the Company’s warrants as of October 31, 2017 is presented below:

 

      Number of  
      warrants  
  Warrants as at April 30, 2017     2,000,000  
  Warrants granted     -  
  Exercised, forfeited or expired     -  
  Outstanding at October 31, 2017     2,000,000  
  Exercisable at October 31, 2017     2,000,000  

 

The following table summarizes information about the warrants as of October 31, 2017:

 

        Warrants
outstanding
    Warrants
exercisable
 
  Exercise
price
    Number
outstanding
    Weighted average
remaining contractual
life (in years)
    Weighted
average
exercise
price
    Number
exercisable
    Weighted
average
exercise
price
 
                                               
  $ 0.001       2,000,000       2.34     $ 0.001       2,000,000     $ 0.001  

 

  9

 

 

10. Stock options

 

During the fiscal year ended April 30, 2013, the Company granted 200,000 stock options for services. The fair value of the stock options granted were estimated on the date granted using the Black-Scholes pricing model, with the following assumptions used for the valuation: exercise price of $0.55 per share, average risk- free interest rate of 0.79%, expected dividend yield of zero, expected lives of five years and an average expected volatility of 2.99%. During the six months ended October 31, 2017 and 2016, the Company recognized expense of nil and nil related to options that vested, respectively.

 

During the six-month period ended October 31, 2017, the Company issued no new stock options.

 

A summary of the status of the Company’s stock options as of October 31, 2017 is presented below:

 

      Number of  
      Shares  
  Balance of stock options as at April 30, 2017     200,000  
  Options granted     -  
  Exercised, forfeited or expired     -  
  Outstanding at October 31, 2017     200,000  
  Exercisable at October 31, 2017     200,000  

 

The following table summarizes information about the stock options as of October 31, 2017:

 

        Options and Warrants     Options and Warrants  
        Outstanding     Exercisable  
              Weighted                    
              Average     Weighted           Weighted  
              Remaining     Average           Average  
  Exercise     Number     Contractual     Exercise     Number     Exercise  
   Prices     Outstanding     Life (in years)      Price     Exercisable     Price  
                                               
  $ 0.80       200,000       1.21     $ 0.80       200,000     $ 0.80

 

  10

 

 

 

Eternity Healthcare Inc.

Notes to the Consolidated Financial Statements

October 31, 2017

(Expressed in U.S. Dollars)

(Unaudited)

 

 

11. Discontinued operations

 

On August 23, 2017, the Company disposed of its intellectual property and its subsidiary, Eternity Healthcare Inc. (British Columbia). The following table presents summarized financial information related to the discontinued operations:

 

      October 31,     April 30,  
      2017     2017  
      $     $  
  Assets            
  Current assets            
  Cash and cash equivalents        -       148,119  
  Prepaid expenses     -       24,230  
  GST/HST receivable     -       1,258  
  Inventory (Note 5)     -       30,283  
                   
  Total assets from discontinued operations     -       203,980  
  Liabilities                
  Current liabilities                
  Accounts payable and accrued liabilities (Note 6)     -       128,607  
  Total liabilities from discontinued operations     -       128,607  

 

      For the three       For the three       For the six        For the six  
      months ended     months
ended
    months ended     months ended  
      October 31,
2017
    October 31,
2016
    October 31,
2017
    October 31,
2016
 
      $     $     $     $  
  Sales                                
  Product sales            -       560       -       2,733  
  Cost of goods sold     -       188       -       1,051  
  Gross margin     -       372       -       1,682  
  Operating Expenses                                
  General and administrative     -       45,434       -       64,995  
  Professional fees     -       -       -       -  
  Research and development     -       1,918       -       21,916  
  Salaries     -       47,183       28,747       81,580  
  Impairment of inventory     -       -       55,210       -  
  Total operating expenses     -       94,535       83,957       168,491  
                                   
  Net loss from discontinued operations     -       (94,163 )     (83,957 )     (166,809 )

  

12. Supplemental cash flow information
   
  During the period ended October 31, 2017, the Company conducted the following non-cash transaction:

 

      October 31,     April 30,  
      2017     2017  
      $     $  
  Related party payable exchanged for intellectual property and shares of subsidiary     79,590       -    

 

13. Subsequent Event
   
  The Company entered into a share exchange agreement (the "Exchange Agreement") dated December 13, 2017, with the equity holders of Guizhou Tongren Healthy China Biotechnology Co. Ltd., a company recently formed in China. Pursuant to the Exchange Agreement, in exchange for an aggregate of 17,181,769 shares of the common stock of the Company, Guizhou Tongren Healthy China Biotechnology Co. Ltd. will become a wholly-owned subsidiary of Eternity Healthcare.  In addition, the Company has acquired all of the outstanding equity of a BVI Company named Trillion Enterprises Group Limited which owns all of the outstanding equity interests in HK Trillion Holdings Limited, a company formed under the laws of Hong Kong.  When the acquisition of Guizhou Tongren Healthy China Biotechnology Co. Ltd. is completed, its shares will be held by the Hong Kong entity, HK Trillion Holdings Limited.

  11

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

General Overview

 

Until the change in control described below, we were a medical device company that, subject to government approval, planned to manufacture and market medical devices. Our new controlling stockholder intends to build a cell storage, transformation and application facility in Tongren, Guizhou Province, China, which will utilize the proprietary biotechnology developed by Shenzhen Zoken Biotechnology Co. LTD. The Company intends to establish a facility in Tongren for the treatment of clients interested in the benefits of stem cell storage and applications, which will have a fully equipped stem cell laboratory, immune cell research room, and a genetics and gene research laboratory. It is estimated that construction of the facility, including acquisition of the equipment, and initial working capital, will require approximately $20 million. It is anticipated that the funds will be provided by affiliates of one of the Company’s shareholders, pursuant to a long-term loan. Pending receipt of the proceeds of such loan, the Company will be dependent upon advances from its shareholders and their affiliates to meet its cash needs.

 

In furtherance of our plan to construct a stem cell facility in China, we entered into a share exchange agreement (the "Exchange Agreement") dated December 13, 2017, with the equity holders of Guizhou Tongren Healthy China Biotechnology Co. Ltd., a company recently formed in China to engage in the business of providing stem cell storage and related medical therapies in China. Pursuant to the Exchange Agreement, in exchange for an aggregate of 17,181,769 shares of the common stock of the Company, Guizhou Tongren Healthy China Biotechnology Co. Ltd. will become a wholly-owned subsidiary of Eternity Healthcare. In addition, we have acquired all of the outstanding equity of a BVI Company named Trillion Enterprises Group Limited which owns all of the outanding equity interests in HK Trillion Holdings Limited, a company formed under the laws of Hong Kong. When the acquisition of Guizhou Tongren Healthy China Biotechnology Co. Ltd. is completed, it will be held by the Hong Kong entity, HK Trillion Holdings Limited.

 

Change In Control and Sale of Subsidiary and Related Intellectual Property and Technology

 

In August 31, 2017, the owners of 53,933,373 shares, representing approximately 76.04% of our outstanding shares of common stock, including the president, chief executive officer and director of our company, sold their shares to Team Youn Bio Medecine International Corp. Limited, a China based company (“Team Youn”). Contemporaneously with the sale, we sold our wholly owned subsidiary, Eternity Health Care Inc., a Canadian Federal corporation, extra-provincially registered in British Columbia (“Eternity BC”), to our former president, chief executive officer and director of our company, and assigned to him certain intellectual property and technology owned by us related to the development, testing and manufacture of our medical device needle free injection technology, together with all “know-how” and other proprietary rights of our company related thereto (the “IP Rights”) for a total purchase price of $CDN100,000 (equivalent to $US80,000). Payment of the purchase price for the shares of the subsidiary and the IP Rights was made by crediting an equal amount against the $CDN1,163,966 ($US941,303) indebtedness owed to our former president, chief executive officer and director for advances made to pay operating expenses. Our remaining $CDN 1,063,966 ($US 861,303) of indebtedness to our former president, chief executive officer and director was assigned to Team Youn.

 

  12

 

 

Results of Operations 

 

As a result of the transfer of Eternity BC as described above and the commencement of our plan to construct a stem cell facility in China, the results of our historical operations are not meaningful to an assessment of the likelihood of success of our future operations. Nevertheless, set forth below is a comparison of the results of our operations for the three and six months ended October 31, 2017 with those of the three and six months ended October 31, 2016.

 

We had no revenues in the three and six month periods ended October 31, 2017, as opposed to the minimal revenues of $560 and $2,733in the three and six month periods ended October 31, 2016, all of which were generated by the discontinued operations of Eternity BC which we sold in August 2017.

 

In connection with the transfer of Eternity BC and the assignment of certain intellectual property and technology owned by us related to the development, testing and manufacture of our medical device needle free injection technology, in consideration for the forgiveness of debt, we generated non-cash gains on the sale of intellectual property of $31,836, which combined with a foreign exchange gain of $75,284, resulted in net income from continued operations for the three and six months ended October 31, 2017, of $77,367 and $53,939, respectively. This compares to net losses incurred in the three and six months ended October 31, 2016, of $22,011 and $53,939, respectively, due to the absence of a foreign exchange gain and a gain on the sale of intellectual property.

 

Liquidity and Capital Resources

 

As of October 31, 2017 we had $0 in cash. We have financed our operations primarily with the proceeds of loans from related parties. During the six months ended October 31, 2017, in anticipation of the sale of the controlling interest in the Company, prior management used all of the $148,119 the Company had on hand as of April 30, 2017, to maintain the Company’s operations and satisfy accounts payable and accrued liabilities, other than amounts due to related parties assigned to Team Youn which was $842,663 as of October 31, 2017. To satisfy our cash requirements for the next 12 months we need additional financing. We are currently in negotiations with an affiliate to one of our shareholders for a loan sufficient to enable us to construct a stem cell facility in Tongren, Guizhou Province, China. We may require additional funds to satisfy our day to day operations, including the cost of operating as a public company. We cannot assure investors that adequate financing will be available to enable us to move forward with our plans to construct a stem facility or to meet the regulatory obligations of a public company. In the absence of such financing, we may be unable to proceed with our plan of operations.

 

Off-Balance Sheet Arrangements

 

We do not maintain any off-balance sheet arrangements, transactions, obligations or other relationships with unconsolidated entities that would be expected to have a material current or future effect upon our financial condition or results of operations.

 

Contractual Obligations

 

As a “smaller reporting company”, we are not required to provide tabular disclosure obligations.

 

Going Concern

 

The interim consolidated financial statements accompanying this report have been prepared on a going concern basis, which implies that our company will continue to realize its assets and discharge its liabilities and commitments in the normal course of business. Our company has not yet established an ongoing source of revenues sufficient to cover our operating expenses and allow us to continue as a going concern. The continuation of our company as a going concern is dependent upon the continued financial support from our stockholders and the ability of our company to obtain adequate capital to fund operating losses until we becomes profitable. Our interim consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should our company be unable to continue as a going concern.

 

  13

 

 

Our interim consolidated financial statements contain additional note disclosures describing the circumstances related to the uncertainty of our ability to continue as a going concern.

 

The issuance of additional equity securities by us could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments.

  

Critical Accounting Policies

 

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financial statements.

   

Principles of Consolidation

 

The consolidated financial statements include the accounts of our company and its wholly-owned subsidiary, Eternity Healthcare Inc. (B.C.) until the date of its sale on August 23, 2017. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include highly liquid investments with original maturities of three months or less.

 

Inventory

 

Inventory is stated at the lower of cost or market with cost determined under the weighted average cost method.

 

Revenue

 

Revenue is recognized at the point of sale and includes shipping revenue for delivery to the purchaser. Total revenues do not include sales taxes as we serve as a pass-through conduit for collecting and remitting sales taxes. We recognize retail sales returns as they occur as historical returns have been negligible.

 

Foreign Currency Translation

 

Our company’s functional currency is the Canadian dollar and reporting currency is the U.S. dollar. All transactions initiated in other currencies are translated into the reporting currency in accordance with ASC 830, “Foreign Currency Matters” as follows:

 

  (i) Assets and liabilities at the rate of exchange in effect at the balance sheet date; and

 

  ( ii) Revenue and expense items at rate of exchange at the dates on which those elements are recognized.

 

Gains and losses on translation are included in other comprehensive income (loss) in stockholders’ deficiency for the period.

 

  14

 

 

Fair Value

 

The carrying value of cash and cash equivalents, accounts receivable, accounts payable and due to related parties approximate their fair values because of the short-term maturity of these financial instruments.

 

Interest Rate Risk

 

Our company is not exposed to significant interest rate risk due to the short-term maturity of its monetary assets and liabilities.

 

Credit Risk

 

Credit risk is the risk of loss associated with counterparty’s inability to fulfill its payment obligations. Our company’s credit risk is primarily attributable to cash and accounting receivable. Management believes that the credit risk concentration with respect to financial instruments included in cash and accounts receivable is remote. 

 

Currency Risk

 

Our company’s operating expenses are primarily incurred in Canadian dollars, and fluctuation of the Canadian dollar in relation to the United States dollar will have an impact upon the profitability of our company and may also have an effect of the value of our company’s. Our company has not entered into any agreements or purchased any instruments to hedge possible currency risk. 

 

Basic and diluted net income (loss) per share

 

The Company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share”. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As at October 31, 2017 there were outstanding stock options and warrants totaling 2,200,000 shares of common stock.  

 

Income Taxes

 

Deferred income taxes are reported for timing differences between items of income or expense reported in the financial statements and those reported for income tax purposes in accordance with ASC 740, “Income Taxes”, which requires the use of the asset/liability method of accounting for income taxes. Deferred income taxes and tax benefits are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and for tax losses and credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Our company provides for deferred taxes for the estimated future tax effects attributable to temporary differences and carry-forwards when realization is more likely than not.

 

Comprehensive Loss

 

ASC 22, “Comprehensive Income”, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As at April 30, 2017, our company has items that represent a comprehensive income (loss) and, therefore, have included a schedule of comprehensive income (loss) in the financial statements.

 

  15

 

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenditures during the reporting period. Actual results could differ from these estimates.

 

Segments of an Enterprise and Related Information

 

ASC 280, “Segment Reporting” establishes guidance for the way that public companies report information about operating segments in annual financial statements and requires reporting of selected information about operating segments in interim financial statements issued to the public. It also establishes standards for disclosures regarding products and services, geographic areas and major customers. ASC 280 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Our company has evaluated this Codification and does not believe it is applicable at this time.

 

Recent Accounting Pronouncements

 

Our company does not expect the adoption of any recent accounting pronouncements to have a material impact on our financial statements.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As a “small reporting company”, we are not required to provide the information required by this Item. 

 

Item 4. Controls and Procedures

 

Management’s Report on Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the  Securities Exchange Act of 1934 , as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer (our principal executive officer, principal financial officer and principle accounting officer) to allow for timely decisions regarding required disclosure.

 

As of the end of our quarter covered by this report, we carried out an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer (our principal executive officer, principal financial officer and principle accounting officer), of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our chief executive officer and chief financial officer (our principal executive officer, principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this quarterly report due to the material weaknesses in our internal controls over financial reporting identified in our Annual Report on Form 10-K for the year ended April 30, 2017. Moreover, as a result of the recent change in control and intent to commence operations in China, we will need to develop sufficient accounting controls and procedures with respect to such activities.

 

Changes in Internal Control over Financial Reporting

 

During the period covered by this report there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

  16

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

 

Item 1A. Risk Factors

 

Reference is made to the risks and uncertainties disclosed in Item 1A (“Risk Factors”) of our Annual Report on Form 10-K for the year ended April 30, 2017 (the “2017 Form 10-K”), which are incorporated by reference into this report. Prospective investors are encouraged to consider the risks described in our 2017 Form 10-K, our Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this report and other information publicly disclosed or contained in documents we file with the Securities and Exchange Commission before purchasing our securities.

 

Item 2. Unregistered Sales of Equity Securities

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mining Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

Exhibit Number   Document Description

10.1

 

 

SHARE EXCHANGE AGREEMENT by and among Eternity Healthcare Inc., Hong Kong Trillion Holdings Limited, and the owners of Guizhou Tongren Healthy China Biotechnology Co. Ltd.,

(31)   Rule 13a-14(a)/15d-14(a) Certifications
31.1   Section 302 Certifications under Sarbanes-Oxley Act of 2002
(32)   Section 1350 Certifications
32.1   Section 906 Certifications under Sarbanes-Oxley Act of 2002
101   Interactive Data Files
101.INS   XBRL Instance Document
101.SCH   XBRL Taxonomy Extension Schema Document
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document

 

  17

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ETERNITY HEALTHCARE INC.
   
Date: January 9, 2018 /s/ Weitao Wang
  Weitao Wang
  President, Chief Executive Officer and
Chief Financial Officer
  (Principal Executive Officer,
Principal Financial Officer and
Principal Accounting Officer)

 

 

18

 

Exhibit 10.1

SHARE EXCHANGE AGREEMENT

 

THIS SHARE EXCHANGE AGREEMENT (hereinafter referred to as this “ Agreement ”) is entered into as of this 13th day of December, 2017, by and among Eternity Healthcare Inc., a Nevada corporation (the “Company”), Hong Kong Trillion Holdings Limited, a company organized under the laws of Hong Kong (“ HK ”), Guizho Tongren Healthy China Biotechnology Co. Ltd., a company organized under the laws of the Peoples’ Republic of China (“Target”) and the stockholders of Target who are signatories to this Agreement (the “ Stockholders ”).

 

Preliminary Statement

 

The Company is a publicly traded company whose shares of common stock are quoted on OTC Pink under the symbol "ETAH.”

 

Target is engaged in the business of providing stem cell storage and related medical therapies in China.

 

HK is a wholly-owned subsidiary of Trillion Enterprises Group Limited, a company organized under the laws of the British Virgin Islands wholly owned by the Company.

 

The Stockholders own all of the outstanding shares of the Target (the “ Target Shares ”).

 

The Company, through HK, desires to acquire 100% of the issued and outstanding shares of Target from the Stockholders in exchange for the issuance of an aggregate of 17,181,769 shares of the common stock of the Company (the “ Exchange Shares ”), and the Stockholders are willing to exchange their shares of Target for the Exchange Shares, on the terms and subject to the conditions set forth herein (the “ Exchange ”). Upon consummation of the Exchange, Target will become a wholly-owned subsidiary of HK.

 

The boards of directors of the Company, HK and Target have determined, subject to the terms and conditions set forth in this Agreement, that the transaction contemplated hereby is desirable and in the best interests of their respective stockholders.  This Agreement is being entered into for the purpose of setting forth the terms and conditions of the proposed acquisition.

 

NOW THEREFORE , on the stated premises and for and in consideration of the mutual covenants and agreements hereinafter set forth and the mutual benefits to the parties to be derived here from, and intending to be legally bound hereby, it is hereby agreed as follows:

 

ARTICLE I

REPRESENTATIONS, COVENANTS, AND WARRANTIES OF TARGET

 

As an inducement to, and to obtain the reliance of the Company, except as set forth in the Target Disclosure Schedules (as defined in Section 1.11 below) annexed hereto, Target represents and warrants as follows:

 

Section 1.01  Organization .  Target has been duly organized and is validly existing, and in good standing under the laws of the Peoples’ Republic of China (“ PRC ”) and has the power and is duly authorized under all applicable laws, regulations, ordinances, and orders of public authorities to carry on its business in all material respects as it is now being conducted.  Target has delivered to the Company or its representatives complete and correct copies of the organizational documents of Target, each as in effect on the date hereof (collectively, the “ Target Charter Documents ”).  The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will not, violate any provision of Target’s Charter Documents.  Target has taken all actions required by law, the Target Charter Documents, or otherwise to authorize the execution and delivery of this Agreement.  Target has full power, authority, and legal capacity and has taken all action required by law, the Target Charter Documents, and otherwise to consummate the transactions herein contemplated.

 

   

 

  

Section 1.02  Subsidiaries and Predecessor Corporations .   Target does not have any subsidiaries, and does not own, beneficially or of record, any shares of or control any other business entity.  

 

Section 1.03    Approval of Agreement.   The Board of Directors of Target has authorized the execution and delivery of this Agreement by Target and the transactions contemplated hereby, and has recommended to the Stockholders that the Exchange be accepted.

 

Section 1.04  Valid Obligation.   This Agreement and all other agreements executed by Target in connection herewith constitute valid and binding obligations of Target, enforceable in accordance with its or their terms, except as may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and subject to the qualification that the availability of equitable remedies is subject to the discretion of the court before which any proceeding therefore may be brought.

 

 Section 1.05  No Conflict With Other Instruments.    The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, constitute a default under, or terminate, accelerate or modify the terms of, any indenture, mortgage, deed of trust, or other material agreement or instrument to which Target is a party or to which any of its assets, properties or operations are subject.

 

Section 1.06  Capitalization .  .  As of the date hereof, the authorized capital of Target consists of _____ shares, of which _____ shares are outstanding.  The issued and outstanding shares of Target are validly issued, fully paid, and non-assessable and not issued in violation of the preemptive or other rights of any person. There are no existing options, warrants, calls, or commitments of any character relating to the authorized and unissued stock of Target.

 

Section 1.07  Financial Statements

 

(a) Target has made available to the Company correct and complete copies of its (i) audited balance sheets as of December 31, 2016 (the “ 2016 Balance Sheet ”) and December 31, 2015 and the related audited statements of operations, stockholders’ equity and cash flows for the year ended December 31, 2016 and December 31, 2015, together with the notes to such statements and the report of its independent certified public accountants thereon, and the unaudited interim balance sheets of Target as of September 30, 2017 and 2016 and the related unaudited statements of operations and cash flows for the nine months ended September 30, 2017 and September 30, 2016, together with the notes to such statements (collectively, the “ Target Financial Statements ”).

 

(b) The Target Financial Statements (including any related notes thereto) were prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto), and each fairly presents in all material respects the financial position of Target at the respective dates thereof and the results of operations and cash flows of Target for the periods indicated, except that the unaudited interim financial statements were or are subject to normal adjustments which were not or are not expected to have a  material adverse effect upon the business, prospects, management, properties, operations, condition (financial or otherwise) or results of operations of Target (“ Material Adverse Effect ”). The balance sheets of Target included in the Target Financial Statements are true and accurate and present fairly as of their respective dates the financial condition of Target.  As of the date of such balance sheets, except as and to the extent reflected or reserved against therein, Target had no liabilities or obligations (absolute or contingent) which should be reflected in the balance sheets of Target or the notes thereto prepared in accordance with U.S. GAAP, and all assets reflected therein are properly reported and present fairly the value of the assets of Target, in accordance with U.S. GAAP. The statements of operations, stockholders’ equity and cash flows of Target reflect fairly the information required to be set forth therein by U.S. GAAP. All of Target’s assets are reflected in the Target Financial Statements, and, except as set forth in the Target Disclosure Schedules or the Target Financial Statements or the notes thereto, as of the respective dates of the Target Financial Statements, Target had no material liabilities, direct or indirect, matured or unmatured, contingent or otherwise.

 

(c) Target has duly and punctually paid all governmental fees and taxes which it has become liable to pay and has duly allowed for all taxes reasonably foreseeable and is under no liability to pay any penalty or interest in connection with any claim for governmental fees or taxation and Target has made any and all proper declarations and returns for taxation purposes and all information contained in such declarations and returns is true and complete and full provision or reserves have been made in its financial statements for all governmental fees and taxation.

 

  2  

 

 

(d) The books and records, financial and otherwise, of Target are in all material respects complete and correct and have been maintained in accordance with generally accepted accounting principles consistently applied throughout the periods involved.

 

Section 1.08  Absence of Certain Changes or Events.   Since September 30, 2017 (the “ Cut-Off Date ”):

 

(a) There has not been (i) any material adverse change in the business, operations, properties, assets or condition of Target, or (ii) any damage, destruction or loss suffered by Target (whether or not covered by insurance), materially and adversely affecting the business, operations, properties, assets or condition of Target.

 

(b) Target has not declared or made, or agreed to declare or make any payment of dividends or distributions of any assets of any kind whatsoever to stockholders or purchased or redeemed, or agreed to purchase or redeem, any of its capital stock; (iii) waived any rights of value which in the aggregate are outside of the ordinary course of its business or material considering its business; (iv) made any material change in its method of management, operation, or accounting; (v) entered into any transactions or agreements other than in the ordinary course of business; (vi) made any accrual or arrangement for or payment of bonuses or special compensation of any kind or any severance or  termination pay to any present or former officer or employee; (vii) increased the rate of compensation payable or to become payable by it to any of its officers or directors or any of its salaried employees whose monthly compensation exceed $1,000; or  (viii) made any increase in any profit sharing, bonus, deferred compensation, insurance, pension, retirement, or other employee benefit plan, payment, or arrangement, made to, for or with its officers, directors, or employees.

 

(c) Target has not (i) granted any options, warrants or rights to purchase, or issued any of its securities; (ii) borrowed or agreed to borrow any funds or incurred, or become subject to, any material obligation or liability (absolute or contingent), except liabilities incurred in the ordinary course of business; (iii) paid or agreed to pay any material obligations or liabilities (absolute or contingent) other than current liabilities reflected in or shown on the Balance Sheet and current liabilities incurred since the Cut-Off Date in the ordinary course of business and professional and other fees and expenses in connection with the preparation of this Agreement and the consummation of the transaction contemplated hereby; (iv) sold or transferred, or agreed to sell or transfer, any of its assets, properties, or rights (except assets, properties, or rights not used or useful in its business which, in the aggregate have a value of less than $1,000), or canceled, or agreed to cancel, any debts or claims (except debts or claims which in the aggregate are of a value less than $1,000); (v) made or permitted any amendment or termination of any contract, agreement, or license to which it is a party if such amendment or termination is material, considering its business; or (vi) issued, delivered or agreed to issue or deliver, any stock, bonds or other corporate securities including debentures (whether authorized and unissued or held as treasury stock), except in connection with this Agreement.

   

(d)  Target has not become subject to any law or regulation which materially and adversely affects, or in the future, may adversely affect, its business, operations, properties, assets or condition.

  

Section 1.09  Litigation and Proceedings .  There are no actions, suits, proceedings, or investigations pending or, to the knowledge of Target after reasonable investigation, threatened against it, or affecting it or its properties, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind.  Target does not have any knowledge of any material default on its part with respect to any judgment, order, injunction, decree, award, rule, or regulation of any court, arbitrator, or governmental agency or instrumentality or of any circumstances which, after reasonable investigation, would result in the discovery of such a default. Target is not a party to or bound by, and its properties are not subject to, any judgment, order, writ, injunction, decree, or award.

 

Section 1.10 PRC Laws and Regulations . Target is in compliance with all applicable laws and regulations of the PRC and the provincial and local governments in which it is located or conducts business, except to the extent that noncompliance would not materially and adversely affect its business, operations, properties, assets, or condition, or result in the occurrence of any material liability,  and all material consents, approvals, authorizations or licenses requisite under PRC law for the due and proper establishment and operation of its business have been duly obtained from the relevant PRC governmental authorities and are in full force and effect.

  3  

 

 

Section 1.11    Target Disclosure Schedules.    Target has delivered to the Company a schedule of any exceptions to the representations made herein (the “ Target Disclosure Schedules ”), certified by the chief executive officer of Target as complete, true, and correct as of the date of this Agreement in all material respects. Target shall promptly update the Target Disclosure Schedules and the information and data delivered to the Company hereunder after the date hereof up to and including the Closing Date.

 

Section 1.12  Information . The information concerning Target set forth in this Agreement and in the Target Disclosure Schedules is complete and accurate in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading.  In addition, Target has fully disclosed in writing to Company (through this Agreement or the Target Disclosure Schedules) all information relating to matters involving Target or its assets or present or past operations or activities which (i) indicated or may indicate, in the aggregate, the existence of a greater than $50,000 liability, (ii) have led or may lead to a competitive disadvantage on the part of Target or (iii) either alone or in aggregation with other information covered by this Section, otherwise have led or may lead to a material adverse effect on Target or its assets, operations or activities as presently conducted or as contemplated to be conducted after the Closing Date, including, but not limited to, information relating to governmental, employee, environmental, litigation and securities matters and transactions with affiliates.

 

ARTICLE II

REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS

 

Each of the Stockholders hereby represents and warrants to the Company, severally and solely, as follows.

 

Section 2.01  Good Title .  The Stockholder is the record and beneficial owner, and has good title to the shares of Target owned by such Stockholder (“ Target Shares ”), with the right and authority to sell and deliver such Target Shares, free and clear of all liens, claims, charges, encumbrances, pledges, mortgages, security interests, options, rights to acquire, proxies, voting trusts or similar agreements, restrictions on transfer or adverse claims of any nature whatsoever.  Upon delivery of any certificate or certificates duly assigned, representing the same as herein contemplated and/or upon registering of the Company as the new owner of such Target Shares in the share register of the Target, the Company will receive good title to such Target Shares, free and clear of all liens.

 

Section 2.02  Power and Authority . The Stockholder has the legal power, capacity and authority to execute and deliver this Agreement to consummate the transactions contemplated by this Agreement, and to perform such Stockholder’s obligations under this Agreement.  This Agreement constitutes a legal, valid and binding obligation of the Stockholder, enforceable against the Stockholder in accordance with the terms hereof.

 

Section 2.03  No Conflicts.   The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of such Stockholder’s obligations hereunder in accordance with the terms hereof: (a) will not require the consent of any third party or governmental entity under any laws; (b) will not violate any laws applicable to the Stockholder and (c) will not violate or breach any contractual obligation to which the Stockholder is a party.

 

Section 2.04  Stockholder is Not a U.S Person and is Acquiring Exchange Shares in an Off-Shore Transaction .

 

(a) The Stockholder understands that it is intended that, and the Company is offering and issuing the Exchange Shares to the Stockholder in reliance on an exemption from the registration requirements of the Securities Act under Regulation S promulgated under the Securities Act (“Regulation S”) based upon the following representations and warranties of the Stockholder: The Stockholder is not a “U.S. Person,” as defined in Rule 902(k) of Regulation S and the issuance and sale of the Exchange Shares will occur in an “off-shore transaction,” as defined in Rule 902 (h) of Regulation S.  The Stockholder has no intention of becoming a U.S. Person, and at the time of the origination of contact concerning this Agreement and the date of the execution and delivery of this Agreement, the Stockholder was outside of the United States.  

  4  

 

Stockholder understands and acknowledges that each certificate representing the Exchange Shares will be endorsed with the following legends, in addition to any other legend required to be placed thereon by applicable federal or state securities laws:

“THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE BEEN OFFERED TO INVESTORS WHO ARE NOT U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“SECURITIES ACT”)) AND WITHOUT REGISTRATION WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT IN RELIANCE UPON REGULATION S PROMULGATED UNDER THE SECURITIES ACT.”

 

“TRANSFER OF THESE SECURITIES IS PROHIBITED, EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S, PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT, OR PURSUANT TO AVAILABLE EXEMPTION FROM REGISTRATION.  HEDGING TRANSACTIONS MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.”

 

(b) The Stockholder acknowledges that neither the SEC, nor the securities regulatory body of any state or other jurisdiction, has received, considered or passed upon the accuracy or adequacy of the information and representations made in this Agreement.

  

(c) The Stockholder acknowledges that he has carefully reviewed such information as he has deemed necessary to evaluate an investment in the Company and its securities.  To the full satisfaction of the Stockholder, the Stockholder has been furnished all materials that he has requested relating to the Company and the issuance of the Exchange Shares hereunder, and the Stockholder has been afforded the opportunity to ask questions of the Company’s representatives to obtain any information necessary to verify the accuracy of any representations or information made or given to the Stockholder.  Notwithstanding the foregoing, nothing herein shall derogate from or otherwise modify the representations and warranties of the Company set forth in this Agreement, on which the Stockholder has relied in making an exchange of the Target Shares for the Exchange Shares.

(d) The Stockholder understands that the Exchange Shares may not be sold, transferred, or otherwise disposed of without registration under the Securities Act or an exemption therefrom, and that in the absence of an effective registration statement covering the Exchange Shares or any available exemption from registration under the Securities Act, the Exchange Shares may have to be held indefinitely.  The Stockholder further acknowledges that the Exchange Shares may not be sold pursuant to Rule 144 promulgated under the Securities Act unless all of the conditions of Rule 144 are satisfied (including, without limitation, the Company’s compliance with the reporting requirements under the Exchange Act).

 

(g) The Stockholder agrees that, notwithstanding anything contained herein to the contrary, the warranties, representations, agreements and covenants of the Stockholder under this Section 2.04 shall survive the Closing for the period set forth in Section 6.11.

 

Section 2.05  Additional Legends; Consent . The Stockholder consents to the Company making a notation on its records or giving instructions to any transfer agent of Exchange Shares in order to implement the restrictions on transfer of the Exchange Shares.

 

ARTICLE III

REPRESENTATIONS, COVENANTS, AND WARRANTIES OF THE COMPANY

 

As an inducement to, and to obtain the reliance of Target and the Stockholders, except as set forth in the Target Disclosure Schedules or the Company SEC Reports (as each of those terms is hereinafter defined), the Company which for purposes of this Article III includes ___ BVI and ____ HK, unless the context requires otherwise) represents and warrants as follows:

 

Section 3.01  Organization . The Company is a corporation duly incorporated, validly existing, and in good standing under the laws of the State of Nevada and has the corporate power and is duly authorized under all applicable laws, regulations, ordinances, and orders of public authorities to carry on its business in all material respects as it is now being conducted.  The Company has made available to Target and the Stockholders or there is included on the Securities and Exchange Commission’s website (“EDGAR”) complete and correct copies of the articles of incorporation and bylaws of the Company, each as in effect on the date hereof (together, the “ Company Charter Documents ”). The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will not, violate any provision of Company Charter Documents.  The Company has taken all action required by law, its Charter Documents, or otherwise to authorize the execution and delivery of this Agreement, and the Company has full power, authority, and legal right and has taken all action required by law, its Charter Documents, or otherwise to consummate the transactions herein contemplated.

 

  5  

 

  

Section 3.02  Subsidiaries.    Except as disclosed in the Company SEC Reports (as defined in Section 3.07 below) and for BVI and HK, the Company does not have any subsidiaries, and does not own, beneficially or of record, any shares of any other corporation.

 

Section 3.03  Approval of Agreement.   The Board of Directors of the Company has authorized the execution and delivery of this Agreement by the Company and has approved this Agreement and the transactions contemplated hereby.

  

Section 3.04  Valid Obligation .  This Agreement and all agreements and other documents executed by Acquirer in connection herewith constitute the valid and binding obligation of the Company, enforceable in accordance with its or their terms, except as may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and subject to the qualification that the availability of equitable remedies is subject to the discretion of the court before which any proceeding therefore may be brought.

 

Section 3.05  No Conflict With Other Instruments.    The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, constitute a default under, or terminate, accelerate or modify the terms of, any indenture, mortgage, deed of trust, or other material agreement or instrument to which the Company is a party or to which any of its assets, properties or operations are subject.

 

Section 3.06  Capitalization. 

 

(a) The authorized capital stock of the Company consists of 300,000,000 shares of common stock, par value $0.001 per share, of which 70,929,868 shares are outstanding. A ll issued and outstanding shares are legally issued, fully paid, and non-assessable and not issued in violation of the preemptive or other rights of any person. There are no existing options, warrants, calls, or commitments of any character relating to the authorized and unissued stock of the Company. No shares of the Company’s common stock were reserved for issuance upon the exercise of outstanding options to purchase the common stock; no shares of common stock were reserved for issuance upon the exercise of outstanding warrants to purchase shares of Company common stock; and no shares of common stock were reserved for issuance upon the conversion of any outstanding convertible notes, debentures or other securities.  All outstanding shares of the Company’s common stock have been issued and granted in compliance with all applicable securities laws and (in all material respects) other applicable laws and regulations.

 

(b) There are no equity securities, partnership interests or similar ownership interests of any class of any equity security of the Company, or any securities exchangeable or convertible into or exercisable for such equity securities, partnership interests or similar ownership interests, issued, reserved for issuance or outstanding. There are no subscriptions, options, warrants, equity securities, partnership interests or similar ownership interests, calls, rights (including preemptive rights), commitments or agreements of any character to which the Company is a party or by which it is bound obligating the Company to issue, deliver or sell, or cause to be issued, delivered or sold, or repurchase, redeem or otherwise acquire, or cause the repurchase, redemption or acquisition of, any shares of capital stock, partnership interests or similar ownership interests of the Company or obligating the Company to grant, extend, accelerate the vesting of or enter into any such subscription, option, warrant, equity security, call, right, commitment or agreement.  There is no plan or arrangement to issue shares of the Company’s common stock, except as set forth in this Agreement.

 

Except as contemplated by this Agreement, there are no registration rights, and there is no voting trust, proxy, rights plan, anti-takeover plan or other agreement or understanding to which the Company is a party or by which it is bound with respect to any equity security of any class of the Company, and there are no agreements to which Company is a party, or of which the Company has knowledge, which conflict with this Agreement or the transactions contemplated herein or otherwise prohibit the consummation of the transactions contemplated hereunder.

 

  6  

 

  

Section 3.07  SEC Filings; Financial Statements

 

(a) The Company has made available to Target and the Stockholders a correct and complete copy, or there has been available on EDGAR, copies, of each report, registration statement and definitive proxy and information statement filed by the Company with the SEC since May 1, 2016 (the “ Company SEC Reports ”). As of their respective dates, the Company SEC Reports: (i) were prepared in accordance and complied in all material respects with the requirements of the Securities Act or the Exchange Act, as the case may be, and the rules and regulations of the SEC thereunder applicable to such Company SEC Reports, and (ii) did not at the time they were filed (and if amended or superseded by a filing prior to the date of this Agreement then on the date of such filing and as so amended or superseded) contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(b) Included in the Company SEC Reports are the audited balance sheets of the Company as of April 30, 2017 and 2016 and the related audited statements of operations and comprehensive loss, stockholders’ equity and cash flows for April 30, 2017 and 2016, together with the notes to such statements and the report of its independent certified public accountants thereon, and the unaudited interim balance sheet of the Company as of October 31, 2017 and the unaudited statements of operations and comprehensive loss and cash flows for the six month and three month periods ended October 31, 2017 and 2016, together with the notes to such statements

 

(c) Each set of financial statements (including, in each case, any related notes thereto) contained in the Company SEC Reports comply as to form in all material respects with the published rules and regulations of the SEC with respect thereto, were prepared in accordance with U.S. GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto) and each fairly presents in all material respects the financial position of the Company at the respective dates thereof and the results of its operations and cash flows for the periods indicated, except that the unaudited interim financial statements were or are subject to normal adjustments which were not or are not expected to have a  material adverse effect upon the business, prospects, management, properties, operations, condition (financial or otherwise) or results of operations of the Company, taken as a whole (“ Material Adverse Effect ”). The balance sheets of the Company included in the Company SEC Reports are true and accurate and present fairly as of their respective dates the financial condition of the Company.  As of the date of such balance sheets, except as and to the extent reflected or reserved against therein, the Company had no liabilities or obligations (absolute or contingent) which should be reflected in the balance sheets or the notes thereto prepared in accordance with U.S. GAAP, and all assets reflected therein are properly reported and present fairly the value of the assets of the Company, in accordance with U.S. GAAP. The statements of operations, stockholders’ equity and cash flows reflect fairly the information required to be set forth therein by U.S GAAP. Except as set forth in the Company Schedules, the Company has no material liabilities, direct or indirect, matured or unmatured, contingent or otherwise.

 

(d) The Company has no material liabilities with respect to the payment of any federal, state, county, local or other taxes (including any deficiencies, interest or penalties), except for taxes accrued but not yet due and payable.

 

(e) Except as set forth in the Company Disclosure Schedules, the Company has timely filed (or filed requests for extensions of time within which to file) all state, federal or local income and/or franchise tax returns required to be filed by it from inception to the date hereof.  Each of such income tax returns reflects the taxes due for the period covered thereby, except for amounts which, in the aggregate, are immaterial.

  

(f) The books and records, financial and otherwise, of the Company are in all material aspects complete and correct and have been maintained in accordance with U.S. GAAP consistently applied throughout the periods involved.

 

  7  

 

 

Section 3.08  Absence of Certain Changes or Events.   Since October 31, 2017:

 

(a) There has not been (i) any material adverse change in the business, operations, properties, assets or condition of the Company or (ii) any damage, destruction or loss to the Company (whether or not covered by insurance) materially and adversely affecting the business, operations, properties, assets or condition of the Company.

 

(b) The Company has not (i) amended the Company Charter Documents, except as may be required by this Agreement; (ii) declared or made, or agreed to declare or make any payment of dividends or distributions of any assets of any kind whatsoever to stockholders or purchased or redeemed, or agreed to purchase or redeem, any of its capital stock; (iii) waived any rights of value which in the aggregate are outside of the ordinary course of business or material considering the business of the Company; (iv) made any material change in its method of management, operation, or accounting; (v) entered into any transactions or agreements other than in the ordinary course of business and as contemplated hereby; (vi) made any accrual or arrangement for or payment of bonuses or special compensation of any kind or any severance or  termination pay to any present or former officer or employee; (vii) increased the rate of compensation payable or to become payable by it to any of its officers or directors or any of its salaried employees whose monthly compensation exceed $1,000; or  (viii) made any increase in any profit sharing, bonus, deferred compensation, insurance, pension, retirement, or other employee benefit plan, payment, or arrangement, made to, for or with its officers, directors, or employees.

 

(c) The Company has not (i) granted or agreed to grant any options, warrants, or other rights for its stock, bonds, or other corporate securities calling for the issuance thereof; (ii) borrowed or agreed to borrow any funds or incurred, or become subject to, any material obligation or liability (absolute or contingent) except liabilities incurred in the ordinary course of business; (iii) paid or agreed to pay any material obligations or liabilities (absolute or contingent) other than current liabilities reflected in or shown on the most recent Company balance sheet and current liabilities incurred since that date in the ordinary course of business and professional and other fees and expenses in connection with the preparation of this Agreement and the consummation of the transaction contemplated hereby; (iv) sold or transferred, or agreed to sell or transfer, any of its assets, properties, or rights (except assets, properties, or rights not used or useful in its business which, in the aggregate have a value of less than $1,000), or canceled, or agreed to cancel, any debts or claims (except debts or claims which in the aggregate are of a value less than $1,000); (v) made or permitted any amendment or termination of any contract, agreement, or license to which it is a party if such amendment or termination is material, considering the business of the Company; or (vi) issued, delivered or agreed to issue or deliver, any stock, bonds or other corporate securities including debentures (whether authorized and unissued or held as treasury stock), except in connection with this Agreement.

 

  (d)  The Company has not become subject to any law or regulation which materially and adversely affects, or in the future, may adversely affect, the business, operations, properties, assets or condition of the Company.

 

Section 3.09  Litigation and Proceedings.   There are no actions, suits, proceedings or investigations pending or, to the knowledge of the Company, threatened against the Company, or affecting the Company or its properties, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind, except as disclosed in the Company Disclosure Schedule 3.09.  The Company is not in default with respect to any judgment, order, writ, injunction, decree, award, rule or regulation of any court, arbitrator, or governmental agency or instrumentality.

 

Section 3.10  Compliance With Laws and Regulations.   The Company has complied with all applicable statutes and regulations of any federal, state, or other applicable governmental entity or agency thereof.

 

  Section 3.11    Company Disclosure Schedules.   The Company has delivered to Target and the Stockholders a schedule of any exceptions to the representations made herein (the “ Company Disclosure Schedules ”), certified by the chief executive officer of the Company as complete, true, and correct as of the date of this Agreement in all material respects. The Company shall promptly update the Company Disclosure Schedules and the information and data delivered to the Target and the Stockholders hereunder after the date hereof up to and including the Closing Date.

 

  8  

 

 

ARTICLE IV

PLAN OF EXCHANGE

 

Section 4.01  The Exchange . On the terms and subject to the conditions set forth in this Agreement, each of the Stockholders by executing this Agreement, shall assign, transfer and deliver, free and clear of all liens, pledges, encumbrances, charges, restrictions or known claims of any kind, nature, or description, the number of shares of Target set forth on Table 1 attached hereto, constituting all of the shares of Target held by such Stockholder. In exchange for the transfer of such securities by the Stockholders, the Company shall issue to the Stockholders, their affiliates or assigns, a total of ______ shares of the Company’s common stock in such proportions as indicated on Table 1 attached hereto. Each of the Stockholders shall, on surrender of their certificate or certificates representing such Stockholder’s shares to the Company or its registrar or transfer agent, be entitled to receive a certificate or certificates evidencing his proportionate interest in the Exchange Shares. The Stockholders acknowledge that the distribution of the Exchange Shares among them has been determined by agreement among them.

Upon consummation of the Exchange, all of the issued and outstanding shares of Target shall be held by the Company.

Section 4.02  Closing.  The closing (the “ Closing ” or the “ Closing Date ”) of the transactions contemplated by this Agreement shall occur contemporaneously with the execution of this Agreement upon the exchange of the shares of Target and the Company as described in Section 4.01 herein.

Section 4.03  Closing Events.  At the Closing, or as soon as reasonably practicable thereafter, the Company, Target and the Stockholders shall execute, acknowledge, and deliver (or shall ensure to be executed, acknowledged, and delivered), any and all certificates, opinions, financial statements, schedules, agreements, resolutions, rulings or other instruments required by this Agreement to be so delivered at or prior to the Closing, together with such other items as may be reasonably requested by the parties hereto and their respective legal counsel in order to effectuate or evidence the transactions contemplated hereby.

 

ARTICLE V

SPECIAL COVENANTS

 

Section 5.01  Delivery of Books and Records.    At the Closing, Target shall deliver to the Company, the originals of the corporate minute books, books of account, contracts, records, and all other books or documents of Target which is now in the possession of Target or its representatives.

Section 5.02  Third Party Consents and Certificates.   Target and the Company agree to cooperate with each other in order to obtain any required third party consents to this Agreement and the transactions herein contemplated.

Section 5.03 Filing of Form 8-K Reporting Share Exchange . The Company will file a Current Report on Form 8-K with the SEC reporting the Share Exchange (the “Share Exchange Form 8-K”) within four business days after the closing of the Share Exchange.

Section 5.04 Target to Deliver to the Company Its Audited Financial Statements for the Year Ended December 31, 2017 . Target will deliver a true and correct copy of its audited financial statements as at and for the year ended December 31, 2017, including a balance sheet at December 31, 2017 and the related statements of operations, stockholders’ equity and cash flows for the year ended December 31, 2017, together with the notes to such statements and the report of its independent certified public accountants thereon, not later than February 28, 2018, for filing as part of an amendment to the Share Exchange Form 8-K.

Section 5.03  Indemnification .

(a) Target hereby agrees to indemnify the Company and each of the officers, agents and directors of Acquirer as of the date of execution of this Agreement against any loss, liability, claim, damage, or expense (including, but not limited to, any and all expense whatsoever reasonably incurred in investigating, preparing, or defending against any litigation, commenced or threatened, or any claim whatsoever) (the “ Loss ”), to which it or they may become subject arising out of or based on any inaccuracy appearing in or misrepresentations made under Article I of this Agreement.  The indemnification provided for in this paragraph shall survive the Closing and consummation of the transactions contemplated hereby and termination of this Agreement for one year following the Closing.

 

  9  

 

  

(b)  Each of the Stockholders, severally but not jointly, agrees to indemnify the Company and each of the officers, agents and directors of the Company as of the date of execution of this Agreement against any Loss, to which it or they may become subject arising out of or based on any inaccuracy appearing in or misrepresentations made under Article II of this Agreement.  The indemnification provided for in this paragraph shall survive the Closing and consummation of the transactions contemplated hereby and termination of this Agreement for one year following the Closing.

 

Section 5.04 The Acquisition of Exchange Shares.  Target and the Company understand and agree that the consummation of this Agreement including the issuance of the Exchange Shares to the Stockholders in exchange for the Exchange Shares as contemplated hereby constitutes the offer and sale of securities under the Securities Act and applicable state statutes.  Target and the Company agree that such transactions shall be consummated in reliance on exemptions from the registration and prospectus delivery requirements of such statutes, which depend, among other items, on the circumstances under which such securities are acquired.

 

(a) In connection with the transaction contemplated by this Agreement, Target and the Company shall each file, with the assistance of the other and their respective legal counsel, such notices, applications, reports, or other instruments as may be deemed by them to be necessary or appropriate in an effort to document reliance on such exemptions, all to the extent and in the manner as may be deemed by such parties to be appropriate.

 

(b) In order to more fully document reliance on the exemptions as provided herein, the Company, Target and the Stockholders shall execute and deliver to the other, at or prior to the Closing, such further letters of representation, acknowledgment, suitability, or the like as the Company or Target and their respective counsel may reasonably request in connection with reliance on exemptions from registration under such securities laws.

 

(c) The Stockholders acknowledge that the basis for relying on exemptions from registration or qualifications are factual, depending on the conduct of the various parties, and that no legal opinion or other assurance will be required or given to the effect that the transactions contemplated hereby are in fact exempt from registration or qualification. 

 

ARTICLE VI

MISCELLANEOUS

 

Section 6.01  Brokers.   Target and the Company agree that, except as set out on Schedule 6.01 attached hereto, there were no finders or brokers involved in bringing the parties together or who were instrumental in the negotiation, execution or consummation of this Agreement.  Target and the Company agree to indemnify the other against any claim by any third person other than those described above for any commission, brokerage, or finder’s fee arising from the transactions contemplated hereby based on any alleged agreement or understanding between the indemnifying party and such third person, whether express or implied from the actions of the indemnifying party.

 

Section 6.02  Governing Law.  This Agreement shall be governed by, enforced, and construed under and in accordance with the laws of the United States of America and, with respect to the matters of state law, with the laws of the State of Nevada.  Venue for all matters shall be in New York, New York, without giving effect to principles of conflicts of law thereunder.  Each of the parties (a) irrevocably consents and agrees that any legal or equitable action or proceedings arising under or in connection with this Agreement shall be brought exclusively in the federal courts of the United States. By execution and delivery of this Agreement, each party hereto irrevocably submits to and accepts, with respect to any such action or proceeding, generally and unconditionally, the jurisdiction of the aforesaid court, and irrevocably waives any and all rights such party may now or hereafter have to object to such jurisdiction.

 

  10  

 

  

Section 6.03  Notices.   Any notice or other communications required or permitted hereunder shall  be in writing and shall be sufficiently given if personally delivered to it or sent by telecopy, overnight courier or registered mail or certified mail, postage prepaid, addressed to the recipient at such address as it has provided to the other parties hereto at the time of execution of this Agreement or such other addresses as shall be furnished in writing by any party in the manner for giving notices hereunder, and any such notice or communication shall be deemed to have been given (i) upon receipt, if personally delivered, (ii) on the day after dispatch, if sent by overnight courier, (iii) upon dispatch, if transmitted by telecopy and receipt is confirmed by telephone and (iv) three (3) days after mailing, if sent by registered or certified mail.

 

                  Section 6.04  Attorney’s Fees.  In the event that either party institutes any action or suit to enforce this Agreement or to secure relief from any default hereunder or breach hereof, the prevailing party shall be reimbursed by the losing party for all costs, including reasonable attorney’s fees, incurred in connection therewith and in enforcing or collecting any judgment rendered therein.

 

Section 6.05  Schedules; Knowledge.  Each party is presumed to have full knowledge of all information set forth in the other party’s schedules delivered pursuant to this Agreement.

 

Section 6.06  Third Party Beneficiaries.  This Agreement is strictly between Target and the Company, and, except as specifically provided, no director, officer, stockholder (other than the Stockholders), employee, agent, independent contractor or any other person or entity shall be deemed to be a third party beneficiary of this Agreement. 

 

Section 6.07  Expenses. Each of Target and the Company will bear their own respective expenses, including legal, accounting and professional fees, incurred in connection with the Exchange or any of the other transactions contemplated hereby.

 

Section 6.08  Entire Agreement.  This Agreement represents the entire agreement between the parties relating to the subject matter thereof and supersedes all prior agreements, understandings and negotiations, written or oral, with respect to such subject matter.

 

Section 6.09  Survival; Termination.  The representations, warranties, and covenants of the respective parties shall survive the Closing Date and the consummation of the transactions herein contemplated for a period of one year.

 

Section 6.10  Counterparts.  This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which taken together shall be but a single instrument.

 

Section 6.11  Amendment or Waiver.  Every right and remedy provided herein shall be cumulative with every other right and remedy, whether conferred herein, at law, or in equity, and may be enforced concurrently herewith, and no waiver by any party of the performance of any obligation by the other shall be construed as a waiver of the same or any other default then, theretofore, or thereafter occurring or existing.  

 

[Signature Pages Follow]

 

  11  

 

 

IN WITNESS WHEREOF , the corporate parties hereto have caused this Agreement to be executed by their respective officers, hereunto duly authorized, as of the date first-above written.

 

Eternity Healthcare Inc.  
     
By: /s/ Weitao Wang  
  Weitao Wang  
   Chief Executive Officer  

 

Hong Kong Trillion Holdings Limited  
     
By: /s/ Yu Yuan Wu  
  Name: Yu Yuan Wu  
  Title:  CTO  

 

Guizho Tongren Healthy China Biotechnology Co. Ltd.  
     
By: /s/ Zheng Jun  
Name: Zheng Jun  
Title: CEO  

 

Accepted and Approved by the Stockholders:  
     
Guizho Tongren Zoken Biotechnology Co. Ltd.  
     
By: /s/ Hu Zhixiong  
  Name: Hu Zhixiong  
  Title:  General Manager  

 

Guizho Zhongjing Times Management Co. Ltd.  
     
By: /s/ Li Jun  
  Name: Li Jun  
 

Title: CFO

 

 

  12  

 

 

 

Table 1

 

   Exchange Shares to be Issued

 

  Name of Stockholder       Number of Exchange Shares       Target Shares  
                  Number         Percent  
                             

 

     

 

  13  

 

 

 

 

 

 

Share Exchange Agreement

Target Disclosure Schedules

Exceptions to Representations  

 

         

 

 

 

  14  

 

 

 

 

 

Share Exchange Agreement

Company Disclosure Schedules

Exceptions to Representations

 

 

 

  15  

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO
18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Weitao Wang, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Eternity Healthcare Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

  

Date: January 9, 2018

 

  /s/ Weitao Wang
  Weitao Wang
 

President, Chief Executive Officer and

Chief Financial Officer

(Principal Executive Officer,

Principal Financial Officer and
Principal Accounting Officer)

Eternity Healthcare Inc.

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Weitao Wang, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) the Quarterly Report on Form 10-Q of Eternity Healthcare Inc. for the period ended October 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Eternity Healthcare Inc.

 

Dated:  January 9, 2018    

  

  /s/ Weitao Wang
  Weitao Wang
  President, Chief Executive Officer and
Chief Financial Officer
(Principal Executive Officer,
Principal Financial Officer and
Principal Accounting Officer)
  Eternity Healthcare Inc.

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Eternity Healthcare Inc. and will be retained by Eternity Healthcare Inc. and furnished to the Securities and Exchange Commission or its staff upon request.